It has been reported that VEGFR-3 also takes part in tumor angiogenesis, and blocking VEGFR-3 signaling with a highly specific VEGFR-3-TKI or monoclonal antibody has shown ability to reduce vascular density.36,40,41 In the current work, we employed two VEGFR-3-TKIs to verify our hypothesis. The gene discussed is FLT4; the disease is neoplasm.